37 Background 38 Antibiotic resistance (ABR) is a quickly worsening problem worldwide, also in low-and middle-income 39 countries (LMICs). Appropriate antibiotic use in humans and animals, i.e. antibiotic stewardship (ABS), is 40 one of the corner stones of the World Health Organization's global action plan for ABR. Many LMICs are 41 in the process of developing stewardship policies and programs. 42 Aims 43 We highlight the challenges for ABS initiatives in LMICs, give an outline of the (inter)national 44 recommendations and demonstrate examples of effective, contextualised stewardship interventions. 45 Sources 46 We searched PubMed for articles on ABS programs and interventions in humans in LMICs. Relevant 47 131 Up-to-date knowledge on optimal antibiotic use was found to be low among physicians and final year 132 medical students in several LMICs(23-25). In addition, ABR was recognized as an important topic by 133 157
. In contrast, solid and generalizable data on cost(effectiveness) of 75 hospital stewardship programs are lacking(4, 6). Fewer studies have been done on interventions 76 targeting outpatient prescribers, but these have also proven to decrease antibiotic prescriptions and 77 resistance rates(7-9). The least evidence is available on the effect and cost-effectiveness of public 78 awareness campaigns, with a limited number of studies showing improved consumer awareness and 79 reduced prescriptions after their (targeted) implementation(10). However, the large majority of studies 80 on ABS have been performed in high-income settings in Europe, the United States (U.S.) and Australia. A 81 systematic review on the effectiveness of ABS in hospitals in LMICs is currently in preparation(11).
82
Additionally, it is important to realize that delayed or no access to antibiotics still kills more people than 83 antibiotic resistant bacteria(12). Therefore, ABS at global scale is not only about reducing inappropriate 84 use, but also about assuring access to effective treatment when necessary.
It is acknowledged that global collaborative action is needed across all resource settings to tackle the 86 problem of ABR. Many LMICs are in the process of developing stewardship policies and programs(13). In 87 this narrative review, we highlight the challenges that ABS initiatives face in LMICs, give an outline of the 88 (inter)national recommendations for ABS and demonstrate examples of effective, contextualised 89 stewardship interventions. This paper focuses on ABS in humans in LMICs. Some of the issues raised are 90 also applicable to the high-income country setting, but may be more significant in LMICs.
92
Search strategy
93
We searched PubMed for articles on ABS interventions in humans in LMICs. The search terms used were 94 "antibiotic stewardship", "antimicrobial stewardship", "Africa", "Asia", "South-America", "resource-95 limited setting", "low-income country" and "middle-income country" or their pertinent translation in 96 Spanish (e.g. programas de optimización de antimicrobianos, uso racional de antimicrobianos, uso 97 prudente de antimicrobianos). We limited the search to guidelines and original studies published within 98 the last five years, written in English or Spanish, and performed in LMICs (according to their annual gross 99 national income per capita in 2015)(14). Relevant websites (e.g. of the WHO, the Pan American Health 100 Organization (PAHO), ReAct) and experts were consulted for additional sources.
102

Stewardship: challenges in LMICs
103
Antibiotic stewardship is challenging in general and even more so when resources -human, laboratory, 104 drugs, policies and formal programs -are limited. We will discuss several challenges that are of particular 105 concern for LMICs. This listing may not be exhaustive, but highlights some of the most prominent Many LMICs face the challenge of both limited access to essential antibiotics, and poorly regulated 147 access to antibiotics. On the one hand, the scarcity of public healthcare facilities in certain rural or 148 remote areas, the high costs of drugs, the absence of sustainable financing systems (e.g. health care 149 insurance), and the lack of a reliable drug supply system limit the access to a wide variety of much-150 needed antibiotics, both older agents with a narrow spectrum (e.g. penicillin, cloxacillin) as well as 151 expensive broad-spectrum antibiotics such as glycopeptides, carbapenems or polymyxins (12, 31, 32) . On 152 the other hand, there is widespread use of non-prescribed antibiotics that can be purchased 'over-the-153 counter'(27). Access to antibiotics without prescription through the internet is another potential 154 threat(33).
155
Perverse financial incentives for prescribers and drug providers, legal concerns and patient demands are 156 additional drivers of antibiotic overuse (19, (34) (35) (36) . The large and growing private sector poses a M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9 particular problem, as in many LMICs its control by regulatory bodies is even more challenging than for 158 the public sector.
159
Of additional concern is the regulation of the quality, safety and efficacy of drugs. Therefore, the 160 confidence in the quality of (generic) medicines is poor -both from the public and health care workers -161 and leads to the prescription of more expensive, non-generic products. Deliberately falsified and 162 substandard drugs appear to be widespread (37, 38) . Donations pose a particular problem in spite of the 163 long-term existence of a WHO guidance in this matter(39). The origin, quality and supply chain of these 164 products may be difficult to trace, and the influence of pharmaceutical companies is often not 
